Helixmith is a gene therapy company developing new and innovative biopharmaceuticals based upon its proprietary scientific platform technology to address unmet medical needs. VM202, the most advanced pipeline candidate, is a plasmid DNA therapy being studied in six different indications including in a currently enrolling phase 3 trial for painful diabetic peripheral neuropathy. Beyond potentially alleviating pain, VM202 is designed to target the underlying causes of neuropathy through its predicted angiogenic and neuroregenerative properties.